• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

    15.55 -0.97 (-5.87%)
    Streaming Delayed Price Updated: 3:29 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,541,499
    Open 16.64
    Bid (Size) 15.54 (300)
    Ask (Size) 15.58 (500)
    Prev. Close 16.52
    Today's Range 15.29 - 17.17
    52wk Range 4.120 - 25.77
    Shares Outstanding 49,383,711
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gapping stocks in Friday's session ↗
    Via Chartmill
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill

    Performance

    YTD
    +1.6%
    +1.6%
    1 Month
    -33.1%
    -33.1%
    3 Month
    -20.5%
    -20.5%
    6 Month
    -25.5%
    -25.5%
    1 Year
    +218.6%
    +218.6%

    More News

    Read More
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
    Via Chartmill
    GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
    Via Stocktwits
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
    Via MarketBeat
    Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Government Stocks
    News headline image
    Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
    Via MarketMinute
    Topics Artificial Intelligence Economy Initial Public Offering
    News headline image
    Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Monte Rosa Therapeutics, Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
    Via Stocktwits
    Wednesday's pre-market session: top gainers and losers ↗
    Via Chartmill

    Frequently Asked Questions

    Is Monte Rosa Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Monte Rosa Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Monte Rosa Therapeutics, Inc. - Common Stock trade on?
    Monte Rosa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock?
    The ticker symbol for Monte Rosa Therapeutics, Inc. - Common Stock is GLUE on the Nasdaq Stock Market
    What is the current price of Monte Rosa Therapeutics, Inc. - Common Stock?
    The current price of Monte Rosa Therapeutics, Inc. - Common Stock is 15.55
    When was Monte Rosa Therapeutics, Inc. - Common Stock last traded?
    The last trade of Monte Rosa Therapeutics, Inc. - Common Stock was at 08/03/26 03:29 PM ET
    What is the market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock?
    The market capitalization of Monte Rosa Therapeutics, Inc. - Common Stock is 767.92M
    How many shares of Monte Rosa Therapeutics, Inc. - Common Stock are outstanding?
    Monte Rosa Therapeutics, Inc. - Common Stock has 768M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.